Shiota M - Search Results

1

Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy.

Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group. Kirisawa T, et al. Among authors: shiota m. Int J Clin Oncol. 2023 Feb;28(2):306-313. doi: 10.1007/s10147-022-02278-7. Epub 2022 Dec 17. Int J Clin Oncol. 2023. PMID: 36527579

2

Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus.

Shiota M, Yokomizo A, Masubuchi D, Tada Y, Inokuchi J, Eto M, Uchiumi T, Fujimoto N, Naito S. Shiota M, et al. Prostate. 2010 Apr 1;70(5):540-54. doi: 10.1002/pros.21088. Prostate. 2010. PMID: 19938016

3

Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.

Shiota M, Eto M, Yokomizo A, Tada Y, Takeuchi A, Masubuchi D, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N, Naito S. Shiota M, et al. Int J Oncol. 2010 Jun;36(6):1521-31. doi: 10.3892/ijo_00000639. Int J Oncol. 2010. PMID: 20428777

4

Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.

Shiota M, Eto M, Yokomizo A, Tada Y, Takeuchi A, Itsumi M, Tatsugami K, Uchiumi T, Naito S. Shiota M, et al. Int J Oncol. 2010 Aug;37(2):509-17. doi: 10.3892/ijo_00000700. Int J Oncol. 2010. PMID: 20596679

5

p300 mediates cellular resistance to doxorubicin in bladder cancer.

Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Tanaka S, Kuroiwa K, Eto M, Naito S. Takeuchi A, et al. Among authors: shiota m. Mol Med Rep. 2012 Jan;5(1):173-6. doi: 10.3892/mmr.2011.593. Epub 2011 Sep 20. Mol Med Rep. 2012. PMID: 21935574

6

Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.

Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S. Takeuchi A, et al. Among authors: shiota m. Int J Oncol. 2012 May;40(5):1691-6. doi: 10.3892/ijo.2012.1368. Epub 2012 Feb 13. Int J Oncol. 2012. PMID: 22344606

7

The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy.

Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S. Shiota M, et al. J Surg Oncol. 2014 Sep;110(4):476-81. doi: 10.1002/jso.23677. Epub 2014 Jun 5. J Surg Oncol. 2014. PMID: 24898352

8

The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.

Shiota M, Yokomizo A, Adachi T, Koga H, Yamaguchi A, Imada K, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S. Shiota M, et al. Jpn J Clin Oncol. 2014 Sep;44(9):860-7. doi: 10.1093/jjco/hyu081. Epub 2014 Jun 20. Jpn J Clin Oncol. 2014. PMID: 24951829

9

The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.

Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S. Shiota M, et al. J Cancer Res Clin Oncol. 2015 Mar;141(3):495-503. doi: 10.1007/s00432-014-1828-7. Epub 2014 Sep 17. J Cancer Res Clin Oncol. 2015. PMID: 25227457 Clinical Trial.

10

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy.

Shiota M, Yokomizo A, Eto M. Shiota M, et al. Front Oncol. 2016 Jan 11;5:304. doi: 10.3389/fonc.2015.00304. eCollection 2015. Front Oncol. 2016. PMID: 26793621 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

787 results

Search Page